Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Melphalan + PVX-410 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Melphalan | Alkeran | Chemotherapy - Alkylating 18 | Alkeran (melphalan) is an antineoplastic alkylating agent, which cross-links DNA and induces cell toxicity and is FDA approved for multiple myeloma and epithelial ovarian carcinoma (FDA.gov). | |
| PVX-410 | PVX 410|PVX410 | PVX-410 is a multipeptide vaccine that may stimulate anti-tumor immune response (PMID: 30128502). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02700841 | Phase II | Melphalan + PVX-410 | Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation | Terminated | USA | 0 |